Log In
Sign Up
Forgotten Password
Upgrade to a paid membership and never see an advert again!
Why do we display adverts? The advertisements supplied by our carefully selected sponsors enable us to host and support the company data we share with our free members.
Watch this company for free updates
Simply enter your email address below and we will send you an email when the company files any documents or there is a change to their credit report.
We require your email address in order to send you alerts by email. You can unsubscribe at any time.
Thank you, you are now watching this company.
You will receive email updates when this company's information changes.
You can choose which alerts you receive and can unsubscribe at any time.
Unlock REPRODUCTIVE MEDICINE TECHNOLOGY TRANSFER LIMITED's Credit Report?
Unlock The Full Report
Upgrade to Lite
Your plan will start immediately and the time remaining on your existing plan will be refunded
Yes, upgrade to Lite
LANCASHIRE HOUSE, 217 UXBRIDGE ROAD, LONDON, W13 9AA
REPRODUCTIVE MEDICINE TECHNOLOGY TRANSFER LIMITED
Private limited with Share Capital
Company is dissolved
01 September 1997
86900 Other human health activities - Commenced trading on 01 09 97 as that of screening tests for cardiovascular desease to assess the ri
Available to 31 Aug 2001. Next accounts due by 31 May 2003
Don't write it off. As exclusively featured on Can't Pay? We'll Take It Away!, DCBL provides a nationwide service recovering over £85 million annually.
Our unique "One Solution" works seamlessly with DCB Legal, managing debt recovery from the first letter through to High Court enforcement.
We act fast to protect your cash flow and recover what you're owed. Recover your debt with the UK's experts.
For a full in-depth analysis on each of these directors, click any of the links below
| Name | Role | Date Of Birth | Appointed |
|---|---|---|---|
| DR ADAM HENRY CAREY | Director | ||
| DR BEVERLY JANE CAREY | Director | ||
| DR BEVERLY JANE CAREY | Company Secretary |
| Accounts |
|---|
| Cash |
| Net Worth |
| Total Current Liabilities |
| Total Current Assets |
Detailed answers about REPRODUCTIVE MEDICINE TECHNOLOGY TRANSFER LIMITED, including incorporation, status, business activity, and accounts information.
REPRODUCTIVE MEDICINE TECHNOLOGY TRANSFER LIMITED was officially incorporated on 01 September 1997 and is registered under company number 03426832. Incorporation establishes the company as a legal entity registered at Companies House, allowing it to trade, enter contracts, and operate under UK company law.
Private limited with Share Capital. This classification indicates the legal structure of the company, which determines the way it is governed, its liability, and regulatory obligations. For example, a private limited company (Ltd) limits the personal liability of its shareholders.
REPRODUCTIVE MEDICINE TECHNOLOGY TRANSFER LIMITED's current status is Dissolved. The company status indicates whether it is actively trading, dormant, or has been dissolved. Maintaining an active status is essential for legally conducting business, filing accounts, and maintaining credibility with partners and lenders.
REPRODUCTIVE MEDICINE TECHNOLOGY TRANSFER LIMITED operates in the following sector: 86900 Other human health activities - Commenced trading on 01 09 97 as that of screening tests for cardiovascular desease to assess the ri . This provides insight into the company’s primary business activities and industry focus. Knowing the SIC code and description is useful for market research, assessing competitors, and understanding potential business risks.
The registered office address of REPRODUCTIVE MEDICINE TECHNOLOGY TRANSFER LIMITED is Lancashire House, 217 Uxbridge Road, London, W13 9AA. This is the official address filed with Companies House for legal and statutory correspondence.
Based on the latest accounts up to 31 Aug 2001, REPRODUCTIVE MEDICINE TECHNOLOGY TRANSFER LIMITED has filed financial statements showing its assets, liabilities, and overall trading performance. The next accounts are due by 31 May 2003. Reviewing these accounts helps assess the company’s financial stability, creditworthiness, and risk profile, which is crucial for investors, suppliers, and potential business partners.